FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
FULGENT GENETICS, INC. (FLGT) had Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $400.00 thousand as of 2024-07-25, per its 10-Q filed 2024-11-08.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2024-11-08
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-12-31 was $5.30M, a 381.82% increase year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-09-30 was $2.30M.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-06-30 was -$100.00K, a 101.79% decline year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $8.10M.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$9.60M, a 580.00% decline from fiscal 2021.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was $2.00M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-07-25 | $400.00K 10-Q · filed 2024-11-08 | |||||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-03 | $5.30M derived: sum of 2 quarters · filed 2024-05-03 | $7.60M derived: sum of 3 quarters · filed 2024-05-03 | $7.50M derived: sum of 4 quarters · filed 2024-08-02 | ||||
| 2023-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $7.60M derived: sum of 2 quarters · filed 2024-02-28 | $7.50M derived: sum of 3 quarters · filed 2024-08-02 | $8.10M 10-K · filed 2024-02-28 | ||||
| 2023-09-30 | $2.30M 10-Q · filed 2023-11-03 | $2.20M derived: sum of 2 quarters · filed 2024-08-02 | $2.80M 10-Q · filed 2023-11-03 | $600.30M derived: sum of 4 quarters · filed 2024-08-02 | ||||
| 2023-06-30 | -$100.00K 10-Q · filed 2024-08-02 | -$140.00K 10-Q · filed 2023-08-04 | $500.00K 10-Q · filed 2024-08-02 | $457.00K 10-Q · filed 2023-08-04 | $598.00M derived: sum of 3 quarters · filed 2024-08-02 | $597.25M derived: sum of 4 quarters · filed 2024-08-02 | ||
| 2023-03-31 | $597.00M 10-Q · filed 2024-05-03 | $597.00K 10-Q · filed 2023-05-05 | $598.10M derived: sum of 2 quarters · filed 2024-05-03 | $597.35M derived: sum of 3 quarters · filed 2024-05-03 | $602.95M derived: sum of 4 quarters · filed 2024-05-03 | |||
| 2022-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $352.00K derived: sum of 2 quarters · filed 2024-02-28 | $5.95M derived: sum of 3 quarters · filed 2024-02-28 | -$9.60M 10-K · filed 2024-02-28 | $9.60M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$748.00K 10-Q · filed 2023-11-03 | $4.85M derived: sum of 2 quarters · filed 2023-11-03 | -$10.70M 10-Q · filed 2023-11-03 | $2.45M derived: sum of 4 quarters · filed 2023-11-03 | ||||
| 2022-06-30 | $5.60M 10-Q · filed 2023-08-04 | $10.00M 10-Q · filed 2023-08-04 | -$8.00M 10-Q · filed 2022-08-04 | $3.20M derived: sum of 3 quarters · filed 2023-08-04 | $3.20M derived: sum of 4 quarters · filed 2023-08-04 | |||
| 2022-03-31 | -$4.40M 10-Q · filed 2023-05-05 | -$2.40M 10-Q · filed 2022-05-05 | -$2.40M derived: sum of 2 quarters · filed 2023-05-05 | -$2.40M derived: sum of 3 quarters · filed 2023-05-05 | ||||
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.00M derived: sum of 2 quarters · filed 2023-02-28 | $2.00M 10-K · filed 2023-02-28 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |